I 
BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Wyeth Europe Ltd submitted on 23 December 1998 an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for 
Rapamune, through the centralised procedure. After agreement by the CPMP on 27 May 1998 this 
medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 
of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Initial assessment 
Rapporteur: 
Evaluators: 
Prof. B. Odlind (until December 1999) 
Dr. P. Nilsson (from December 1999) 
Dr. S.-E. Hillver 
Dr. S. Hovmark 
Dr. I. Anundi 
Dr. M. Gårdmark   
Dr. P. Nilsson 
Appeal 
Rapporteur:  Dr. D. Brasseur 
Evaluators: 
Prof. D. Abramowicz 
Dr. M. Zeicher 
Licensing status: 
Co-Rapporteur:  Prof. S. Garattini 
Evaluators: 
Dr. C. Caramella 
Dr. M. Terreni 
Dr. I. Bartosek  
Dr. S. Caccia 
Dr. J. Golay 
Dr. N. Perico 
Dr. G. Remuzzi 
Co-Rapporteur:   Prof. R. Bass 
Dr. R. Lehnert 
Dr. U. Fürstenau 
At the time of the initial submission Rapamune had not been given a Marketing Authorisation 
anywhere. 
2. 
Steps taken for the assessment of the product 
 
 
 
 
 
 
 
 
 
The procedure started on 29 January 1999. 
The Rapporteur's assessment report was circulated to all CPMP Members on 9 April 1999. The 
Co-Rapporteur's first assessment report was circulated to all CPMP Members on 12 April 1999. 
On 27 April 1999 the applicant informed Rapporteur and Co-Rapporteur about an error in the 
efficacy data analyses. During the meeting on 18-20 May 1999 the CPMP decided to stop the 
clock of the procedure in order to allow the applicant to submit an amended Efficacy Summary. 
The  corrected  Efficacy  Summary  was  submitted  on  7  June  1999.  The  Rapporteur's  revised 
assessment report was circulated to all CPMP Members on 17 June 1999. The Addendum to the 
Co-Rapporteur's first assessment report was circulated to all CPMP Members on 22 June 1999. 
During the meeting on 27-29 July 1999 the CPMP agreed on the consolidated list of questions 
to be sent to the applicant. The final consolidated list of questions was sent to the applicant on 
30 July 1999. 
The Applicant submitted the responses to the consolidated list of questions on 21 January 2000. 
The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  on  8-9  December 
2000 was issued on 20 March 2000. 
The Rapporteur circulated the response assessment report on the applicant’s responses to the list 
of  questions  to  all  CPMP  Members  on  22  March  2000.  A  revised  overall  conclusion  and 
assessment report on Part II was circulated to all CPMP Members on 4 April 2000. 
During the meeting on 11-12 April 2000 the CPMP agreed on the list of outstanding issues to be 
sent to the applicant. This list was sent to the applicant on 13 April 2000. 
CPMP/4206/00 
1/3 
EMEA 2001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  applicant  submitted  written  responses  to  the  consolidated  list  of  outstanding  issues  on  
14 June 2000. 
The  Rapporteur  circulated  the  response  assessment  report  on  the  Applicant's  responses  to  the 
list of outstanding issues to all CPMP Members on 11 July 2000. 
During the CPMP meeting on 25 July 2000, outstanding issues were addressed by the applicant 
during an oral explanation before the CPMP.  
During the meeting on 25-27 July 2000 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  negative  opinion  for  granting  a 
Marketing Authorisation to Rapamune on 27 July 2000. 
3. 
Steps taken for the appeal procedure 
 
 
 
 
 
 
 
A  valid  intent  for  appeal  against  the  CPMP  Opinion  on  Rapamune  was  submitted  by  the 
applicant, Wyeth Europa Ltd, on 17 August 2000. 
Grounds for appeal were submitted by the applicant on 13 September 2000. 
During  its  meeting  on  19-21  September  2000,  the  CPMP  appointed  Dr.  D.  Brasseur  as 
Rapporteur and Prof. R. Bass as Co-Rapporteur for the appeal procedure. 
The Rapporteur’s assessment report was circulated to all CPMP members on 26 October 2000 
(Annex 1) and the Co-Rapporteur’s assessment report was circulated to all CPMP members on 
31 October 2000 (Annex 2). 
An  expert  panel  meeting  was  held  on  13  November  2000.  The  report  of  the  expert  panel 
meeting was circulated to all CPMP members on 14 November 2000 (Annex 3).  
During  the  meeting  on  14-16  November  2000,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Rapamune.  
The  CPMP  Opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 13 March 2001. 
CPMP/4206/00 
2/3 
EMEA 2001 
 
II  GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION 
1.  Manufacturing Authorisation Holder and inspection status 
Manufacturers of the active substance for 
Oral Solution 
Manufacturers of the active substance for 
Tablets 
Mercian Corporation 
Iwata Plant 
1808 Nakaizumi 
Iwata-shi 
Shizuoka 
Japan 
Wyeth-Ayerst Laboratories 
Maple Street 
Rouses Point 
NY, 12979 
USA 
Manufacturers of the finished product 
Wyeth-Ayerst Laboratories 
Maple Street 
Rouses Point 
NY, 12979 
USA 
PACO Pharmaceutical Services, Inc. 
1200 Paco Way 
Lakewood, NJ 08701 
USA 
Wyeth Medica Ireland 
Little Connell 
Newbridge, Co. Kildare 
Ireland 
Mercian Corporation 
Iwata Plant 
1808 Nakaizumi 
Iwata-shi 
Shizuoka 
Japan 
Wyeth-Ayerst Laboratories 
Maple Street 
Rouses Point 
NY, 12979 
USA 
Manufacturers of the finished product 
(Manufacture of sirolimus NanoSytems Dispersion 
only:) 
NanoSystems, Division of Elan 
Pharmaceutical Technologies 
3000 Horizon Drive 
King of Prussia 
PA 19406 
USA 
At:Pharmaceutical Manufacturing Research 
Services Inc. (PMRS) 
423 Sargon Way 
Horsham 
PA 19044 
USA 
(Manufacture of the coated tablets:) 
Wyeth-Ayerst Laboratories 
Maple Street 
Rouses Point 
NY, 12979 
USA 
(Site for printing and testing of the coated 
tablets and alternate site for manufacture of 
the compressed inert tablet core:) 
Wyeth Pharmaceutical Company 
Highway no.3, Km 142.1 
Barrios Pozo Hondos and Jobos 
Guayama 
Puerto Rico 00784 
Manufacturer responsible for batch release 
Manufacturer responsible for batch release 
Wyeth Laboratories 
New Lane 
Havant 
Hants PO9 2NG 
United Kingdom 
CPMP/4206/00 
Wyeth Laboratories 
New Lane 
Havant 
Hants PO9 2NG 
United Kingdom 
3/3 
EMEA 2001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manufacturing Authorisation issued on 28 January 1999 by the Irish Medicines Board. 
2. 
Conditions or restrictions regarding supply and use 
Medicinal product subject to restricted medical prescription (refer to section 4.2 of the Summary of 
Product Characteristics for further information). 
CPMP/4206/00 
4/3 
EMEA 2001 
 
